The ongoing evolution of proteomics in malignancy.
The complementary fields of genomics and proteomics offer insights into the molecular mechanisms of diseases. While genomics seeks to define our genetic substrate, proteomics explores the structure and function of proteins, which are the end effectors of our genes. Proteomics has been revolutionized in the past decade by the application of techniques such as protein arrays, two-dimensional gel electrophoresis, and mass spectrometry. These techniques have tremendous potential for biomarker development, target validation, diagnosis, prognosis, and optimization of treatment in medical care, especially in the field of clinical oncology. We will discuss innovations in proteomic technologies and highlight their prospective applications to patient care.
Dhamoon
Amit S
AS
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr. MSC 1500, Bethesda, MD 20892, United States.
Kohn
Elise C
EC
Azad
Nilofer S
NS
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D015180:Electrophoresis, Gel, Two-Dimensional; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D013058:Mass Spectrometry; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D040081:Protein Array Analysis; D020543:Proteome / Q000032:analysis*; D040901:Proteomics / Q000379:methods*